New drug combo may reduce deadly transplant complication in blood cancer patients
NCT ID NCT04339101
First seen Apr 08, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This study tested whether adding the drug itacitinib to the usual two-drug regimen (tacrolimus and sirolimus) could better prevent graft-versus-host disease (GVHD) in 59 adults with blood cancers (acute leukemia, myelodysplastic syndrome, or myelofibrosis) undergoing a donor stem cell transplant. GVHD occurs when donor immune cells attack the patient's body. The goal was to see if this three-drug combination improves survival and reduces severe GVHD without increasing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.